TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16572123

Group type: EXPERIMENTAL
Intervention: THC 250 microg/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: THC 500 microg/kg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (0 microg/kg THC)
Number of subjects: 20
Study: 12679450

Group type: EXPERIMENTAL
Intervention: 30 mg pioglitazone (up to 45 mg for 77% of patients)
Number of subjects: 205

Group type: COMPARATOR
Intervention: 850 mg metformin (up to 2550 mg for 73% of patients)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: 30 mg pioglitazone
Number of subjects: 205

Group type: COMPARATOR
Intervention: 850 mg metformin
Number of subjects: 205
Study: 10889818

Group type: EXPERIMENTAL
Intervention: Aspergillus antigen ELISA
Number of subjects: 104

Group type: COMPARATOR
Intervention: Latex agglutination (LA) test
Number of subjects: 104
Study: 8770436

Group type: EXPERIMENTAL
Intervention: Sequential treatment group: 8 weeks with a self-care manual followed by up to eight sessions of CBT if still symptomatic.
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard treatment group: 16 sessions of CBT.
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Self-care manual (part of the sequential treatment).
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Sequential treatment group.
Number of subjects: 110
Study: 1593057

Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg twice daily for 6 months
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg twice daily
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study: 6323667

Group type: EXPERIMENTAL
Intervention: Topical antibiotic therapy (polymyxin-bacitracin ophthalmic ointment) applied four times a day for 7 days
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Topical antibiotic therapy (polymyxin-bacitracin ophthalmic ointment)
Number of subjects: 102
Study: 31420274

Group type: EXPERIMENTAL
Intervention: Uric acid levels in the 3rd tertile (≥327 μmol/L)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: High uric acid levels (≥327 μmol/L)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: High modified Rankin Scale score
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 191
Study: 29409923

Group type: EXPERIMENTAL
Intervention: Hot snare polypectomy (HSP)
Number of subjects: 269
Study: 27734491

Group type: EXPERIMENTAL
Intervention: Humidified oxygen at 60 l.min‐1 via nasal prongs (OptiflowTM) with the mouth closed
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Humidified oxygen at 60 l.min‐1 via nasal prongs (OptiflowTM) with the mouth open
Number of subjects: 10

Group type: COMPARATOR
Intervention: Face mask oxygenation at 10 l.min‐1
Number of subjects: 10
Study: 24670704

Group type: EXPERIMENTAL
Intervention: Treatment-induced decrease in CXCL10 levels in patients with 'insufficient' and 'deficient' vitamin D levels.
Number of subjects: 0

Group type: COMPARATOR
Intervention: CXCL10 levels in patients with 'optimal' vitamin D levels.
Number of subjects: 0
Study: 23241929

Group type: EXPERIMENTAL
Intervention: Lady Prelox
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 20695797

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient (MM) supplementation
Number of subjects: 287

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287
Study: 17506789

Group type: EXPERIMENTAL
Intervention: Aromatherapy
Number of subjects: 251

Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 251
Study: 15849477

Group type: EXPERIMENTAL
Intervention: Hemodialysis patients
Number of subjects: 160
Study: 12468337

Group type: EXPERIMENTAL
Intervention: Intraperitoneal mitoxantrone
Number of subjects: 31

Group type: COMPARATOR
Intervention: Intraperitoneal fluorodeoxyuridine (FUDR)
Number of subjects: 31
Study: 10086702

Group type: EXPERIMENTAL
Intervention: 18F alpha-methyl tyrosine (FMT) PET imaging
Number of subjects: 31
Study: 7677556

Group type: EXPERIMENTAL
Intervention: Proxy information distributed before the day of admission
Number of subjects: 419

Group type: COMPARATOR
Intervention: Proxy information distributed only on the day of admission
Number of subjects: 419
Study: 2183111

Group type: EXPERIMENTAL
Intervention: Local anesthesia
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dorsal penile nerve block
Number of subjects: 30

Group type: COMPARATOR
Intervention: Unanesthetized control
Number of subjects: 30
Study: 6265162

Group type: EXPERIMENTAL
Intervention: Cefotaxime (3 h) before surgery for 4 days
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control (no antibiotic prophylaxis)
Number of subjects: 70
Study: 30883233

Group type: EXPERIMENTAL
Intervention: 20% benzocaine gel
Number of subjects: 100

Group type: COMPARATOR
Intervention: No topical agent
Number of subjects: 100
Study: 29156909

Group type: EXPERIMENTAL
Intervention: Palliative radiotherapy (RT) with a single 8 Gy dose
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Single-nucleotide variants (SNVs) identified through saliva sequencing
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Specific SNVs (e.g., AOAH rs7986, ZAN rs539445, RAG1 rs3740955)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Deletion at position 111992032 in the ataxin gene ATXN2
Number of subjects: 107
Study: 25428176

Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine 0.5% (4 drops daily)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Dorzolamide hydrochloride 2% (3 drops daily)
Number of subjects: 18
Study: 24407835

Group type: EXPERIMENTAL
Intervention: Mammography and ultrasonography (standardized examination)
Number of subjects: 76196

Group type: COMPARATOR
Intervention: Mammography (control group)
Number of subjects: 76196
Study: 22837629

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.5% with lidocaine 2%
Number of subjects: 150

Group type: COMPARATOR
Intervention: Bupivacaine 0.5% with lidocaine 2%
Number of subjects: 150
Study: 19884468

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 57
Study: 17578316

Group type: EXPERIMENTAL
Intervention: Shenqi Fuzheng Injection (SFI) in cooperation with chemotherapy (CAF protocol)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Chemotherapy (CAF protocol) alone
Number of subjects: 110
Study: 15163260

Group type: EXPERIMENTAL
Intervention: Risperidone plus mood stabilizer (mean dose 3.8 mg/day during the 3-week study and 3.1 mg/day during the 10-week study)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Risperidone plus mood stabilizer
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo plus mood stabilizer
Number of subjects: 156
Study: 11298104

Group type: EXPERIMENTAL
Intervention: 1072 nm narrow waveband light application (single 5 min treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical aciclovir (applied five times daily)
Number of subjects: 0
Study: 9869347

Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR) with bioresorbable barrier membranes
Number of subjects: 23

Group type: COMPARATOR
Intervention: Access flap surgery
Number of subjects: 23

Group type: COMPARATOR
Intervention: Access flap surgery in shallow defects (INFRA ≤3 mm)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Access flap surgery in deep defects (INFRA ≥4 mm)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR) in shallow defects
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR) in deep defects
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR)
Number of subjects: 23
Study: 8018978

Group type: EXPERIMENTAL
Intervention: Nizatidine 150 mg/day
Number of subjects: 61

Group type: COMPARATOR
Intervention: Ranitidine 150 mg/day
Number of subjects: 61
Study: 2685599

Group type: EXPERIMENTAL
Intervention: Cod-liver oil
Number of subjects: 18

Group type: COMPARATOR
Intervention: Olive oil
Number of subjects: 18
Study: 10874

Group type: EXPERIMENTAL
Intervention: Heart rate feedback during treatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Instructions to lower heart rate without feedback
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Heart rate feedback added to instructions
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Self-control of heart rate with biofeedback
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pretreatment training in self-control of heart rate with feedback
Number of subjects: 10
Study: 31818818

Group type: EXPERIMENTAL
Intervention: 5-day artemether-lumefantrine regimen
Number of subjects: 96

Group type: COMPARATOR
Intervention: 3-day artemether-lumefantrine regimen
Number of subjects: 96
Study: 30476489

Group type: EXPERIMENTAL
Intervention: WheelSeeU (peer-led program)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (professional-led didactic information sessions)
Number of subjects: 40
Study: 26917627

Group type: EXPERIMENTAL
Intervention: Acupuncture (in addition to standard medical care)
Number of subjects: 182
Study: 25967378

Group type: EXPERIMENTAL
Intervention: Body-mind-spirit intervention (n = 56)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Treatment-as-usual (n = 64)
Number of subjects: 120
Study: 23935161

Group type: EXPERIMENTAL
Intervention: Multimedia intervention group (n = 18)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (n = 17)
Number of subjects: 35
Study: 21114478

Group type: EXPERIMENTAL
Intervention: Isotretinoin at 0·5‐0·7 mg kg⁻¹ daily for 24 weeks (group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Isotretinoin at 0·25‐0·4 mg kg⁻¹ daily for 24 weeks (group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Isotretinoin at 0·5‐0·7 mg kg⁻¹ daily for 1 week out of every 4 weeks for 6 weeks (group C)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Isotretinoin at 0·25‐0·4 mg kg⁻¹ daily (group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Isotretinoin at 0·5‐0·7 mg kg⁻¹ daily (group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Isotretinoin at 0·5‐0·7 mg kg⁻¹ daily for 1 week out of every 4 weeks (group C)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional treatment (group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low-dose treatment (group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intermittent treatment (group C)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Follow-up after 1 year (group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Follow-up after 1 year (group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Follow-up after 1 year (group C)
Number of subjects: 60
Study: 19360238

Group type: EXPERIMENTAL
Intervention: Carotid sinus massage (CSM) performed in the supine position for 10 seconds
Number of subjects: 502
Study: 17084325

Group type: EXPERIMENTAL
Intervention: Anxiety-inducing, bursting balloon
Number of subjects: 81

Group type: COMPARATOR
Intervention: Nonbursting balloon
Number of subjects: 81
Study: 15627789

Group type: EXPERIMENTAL
Intervention: Continuous ambulatory peritoneal dialysis (CAPD) in FMF-amyloidosis patients
Number of subjects: 40

Group type: COMPARATOR
Intervention: Diabetes mellitus (DM) patients
Number of subjects: 40

Group type: COMPARATOR
Intervention: FMF-amyloidosis patients
Number of subjects: 40
Study: 11242425

Group type: EXPERIMENTAL
Intervention: Experimental intervention (n = 16) modeled on the Baby‐Friendly Hospital Initiative emphasizing health care worker assistance with initiating and maintaining breastfeeding and lactation and postnatal breastfeeding support.
Number of subjects: 17046

Group type: EXPERIMENTAL
Intervention: Experimental intervention (n = 16)
Number of subjects: 17046

Group type: COMPARATOR
Intervention: Control intervention (n = 15) of continuing usual infant feeding practices and policies.
Number of subjects: 17046
Study: 9577500

Group type: EXPERIMENTAL
Intervention: Silver-coated catheter (n = 47)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Identical catheter without silver coating (n = 44)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Both groups (n = 72 completion venograms)
Number of subjects: 91
Study: 8004602

Group type: EXPERIMENTAL
Intervention: Screening for breast cancer
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Modern mammography
Number of subjects: 5
Study: 3504404

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Carbamazepine (CBZ)
Number of subjects: 40
Study: 28140705

Group type: EXPERIMENTAL
Intervention: Multifunctional airbag abdominal pressure belt during the second and third stages of labor
Number of subjects: 363

Group type: COMPARATOR
Intervention: Control group (no belt used)
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Multifunctional airbag abdominal pressure belt
Number of subjects: 363
Study: 27126851

Group type: EXPERIMENTAL
Intervention: Nurse home visits (NHV)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Maternal mental health (MH)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Maternal mastery
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Maternal smoking
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Genetic polymorphisms (FKBP5 rs1360780, 5‐HTTLPR, DRD2/ANKK1 rs1800497)
Number of subjects: 600
Study: 25057981

Group type: EXPERIMENTAL
Intervention: Investigative CT protocol with iterative reconstruction at conventional radiography dose levels
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Investigative CT protocol
Number of subjects: 38
Study: 22429944

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 20039196

Group type: EXPERIMENTAL
Intervention: 8-week Internet-based cognitive-behavioral treatment
Number of subjects: 124

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 124
Study: 18541100

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of meglumine antimoniate (20 mg Sb/kg/day, maximum 850 mg) for 21 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intralesional injection of meglumine antimoniate (0.5 mL, 42.5 mg of Sb) into each lesion along with intramuscular injection of meglumine antimoniate (20 mg Sb/kg/day, maximum 850 mg) for 21 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 60
Study: 16326295

Group type: EXPERIMENTAL
Intervention: Magnesium group (2.5 g magnesium sulphate infusion intraoperatively over 30 minutes)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo group (normal saline solution)
Number of subjects: 160
Study: 12819504

Group type: EXPERIMENTAL
Intervention: Laparoscopic totally extraperitoneal approach (TEP) repair
Number of subjects: 134

Group type: COMPARATOR
Intervention: Open mesh repair
Number of subjects: 134
Study: 11119180

Group type: EXPERIMENTAL
Intervention: Cue-dose training combined with cash reinforcement (CD+CR)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Cue-dose training (CD)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Cash-reinforced group (CD+CR)
Number of subjects: 55
Study: 9049196

Group type: EXPERIMENTAL
Intervention: Propranolol administration
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 8327595

Group type: EXPERIMENTAL
Intervention: Human insulin (0.035 IU/kg body weight)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Conditioned stimulus (CS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 30
Study: 3755281

Group type: EXPERIMENTAL
Intervention: MAP (mitomycin C, doxorubicin, and cisplatin)
Number of subjects: 130

Group type: COMPARATOR
Intervention: CAP (cyclophosphamide, doxorubicin, and cisplatin)
Number of subjects: 130
Study: 29534874

Group type: EXPERIMENTAL
Intervention: VT‐1161 150 mg once daily for 7 days, then 150 mg once weekly for 11 weeks, followed by a once‐weekly dose of placebo for 12 weeks
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: VT‐1161 300 mg once daily for 7 days, then 300 mg once weekly for 11 weeks, followed by a once‐weekly dose of placebo for 12 weeks
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: VT‐1161 150 mg once daily for 7 days, then 150 mg once weekly for 23 weeks
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: VT‐1161 300 mg once daily for 7 days, then 300 mg once weekly for 23 weeks
Number of subjects: 215

Group type: COMPARATOR
Intervention: Placebo regimen for 24 weeks
Number of subjects: 215
Study: 27234671

Group type: EXPERIMENTAL
Intervention: Once-weekly teriparatide therapy for 72 weeks
Number of subjects: 0
Study: 24719911

Group type: EXPERIMENTAL
Intervention: LY2605541
Number of subjects: 425

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 425
Study: 23291317

Group type: EXPERIMENTAL
Intervention: Tomato juice administered during and after exercise for over a 2-month period
Number of subjects: 15

Group type: COMPARATOR
Intervention: Carbohydrate supplementation (control group)
Number of subjects: 15
Study: 21159597

Group type: EXPERIMENTAL
Intervention: RSA performed within 1 hour after skin closure
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: RSA performed at 1 day after surgery
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: RSA performed at 7 days after surgery
Number of subjects: 24
Study: 18303533

Group type: EXPERIMENTAL
Intervention: Laparoscopic radical nephrectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open radical nephrectomy
Number of subjects: 0
Study: 16911143

Group type: EXPERIMENTAL
Intervention: Video decision aid
Number of subjects: 1152

Group type: EXPERIMENTAL
Intervention: Pamphlet decision aid
Number of subjects: 1152

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 1152
Study: 14714355

Group type: EXPERIMENTAL
Intervention: Milkvetch Injection (15 ml every 12 hrs for 7 days)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional treatment (Control group)
Number of subjects: 32
Study: 10946527

Group type: EXPERIMENTAL
Intervention: Cerivastatin (0.3 mg)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Pravastatin (20 mg)
Number of subjects: 402
Study: 9063919

Group type: EXPERIMENTAL
Intervention: 50 micrograms sufentanil in 50 ml 0.125% bupivacaine (group 1)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 150 micrograms clonidine in 50 ml 0.125% bupivacaine (group 2)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 50 micrograms sufentanil + 150 micrograms clonidine in 50 ml 0.125% bupivacaine (group 3)
Number of subjects: 45
Study: 31652452

Group type: EXPERIMENTAL
Intervention: PHOX2B rs28647582 T>C polymorphism (TC/CC genotypes)
Number of subjects: 145

Group type: COMPARATOR
Intervention: TT genotype
Number of subjects: 145
Study: 29119331

Group type: EXPERIMENTAL
Intervention: 100% DAA diet
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: 107% DAA diet
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: 114% DAA diet
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: All DAA levels
Number of subjects: 480
Study: 26896318

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (MgSO4)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study: 24974817

Group type: EXPERIMENTAL
Intervention: AREDS supplements (placebo, antioxidants (vitamin C, vitamin E, β-carotene), zinc, or a combination)
Number of subjects: 1237

Group type: EXPERIMENTAL
Intervention: AREDS supplements
Number of subjects: 1237
Study: 22323011

Group type: EXPERIMENTAL
Intervention: Apical pleurectomy
Number of subjects: 160

Group type: COMPARATOR
Intervention: Pleural abrasion with minocycline
Number of subjects: 160
Study: 18317179

Group type: EXPERIMENTAL
Intervention: Resistive exercise countermeasure with whole-body vibration
Number of subjects: 20

Group type: COMPARATOR
Intervention: Inactive control group
Number of subjects: 20
Study: 17187005

Group type: EXPERIMENTAL
Intervention: Diane 35 (cyproterone acetate 2 mg with ethinylestradiol 35 µg) for 6 months
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (11 healthy women, mean age 26.0±2.6 years)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Ghrelin levels
Number of subjects: 25
Study: 14733989

Group type: EXPERIMENTAL
Intervention: New safety training curriculum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual training
Number of subjects: 0
Study: 10852597

Group type: EXPERIMENTAL
Intervention: Simultaneous double kidney transplantation (SDKT) from donors aged 75 years or older.
Number of subjects: 181

Group type: COMPARATOR
Intervention: Single kidney transplantation from donors aged 60-74 years with GE <15%.
Number of subjects: 181

Group type: COMPARATOR
Intervention: Single kidney transplantation from donors <60 years of age.
Number of subjects: 181

Group type: COMPARATOR
Intervention: All groups (I, II, III) for primary nonfunction rate.
Number of subjects: 181

Group type: COMPARATOR
Intervention: All groups (I, II, III) for acute rejection rates.
Number of subjects: 181

Group type: COMPARATOR
Intervention: All groups (I, II, III) for one year actuarial patient survival rates.
Number of subjects: 181

Group type: COMPARATOR
Intervention: All groups (I, II, III) for graft survival rates.
Number of subjects: 181

Group type: COMPARATOR
Intervention: All groups (I, II, III) for 6-month serum creatinine levels.
Number of subjects: 181
Study: 9086582

Group type: EXPERIMENTAL
Intervention: T3 (0.6 microgram/kg bolus)
Number of subjects: 0

Group type: COMPARATOR
Intervention: T3 (0.2 microgram/kg bolus, 0.4 microgram/kg infusion over 6 hours)
Number of subjects: 0
Study: 8412266

Group type: EXPERIMENTAL
Intervention: Postoperative cisplatin and vindesine chemotherapy
Number of subjects: 209

Group type: COMPARATOR
Intervention: No further treatment (Control)
Number of subjects: 209
Study: 2870661

Group type: EXPERIMENTAL
Intervention: Akrinor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: etilefrine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ephedrine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: norfenefrine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ameziniummetilsulfate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 30586843

Group type: EXPERIMENTAL
Intervention: Cashew nuts (42 g/day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Cashew-containing diet
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 18
Study: 27097695

Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation (EVL)
Number of subjects: 47